Forwarded by the Los Angeles County Department of Public Health
Forwarded by the Los Angeles County Department of Public Health
CDPH Health Advisory:
Bamlanivimab plus Etesevimab No Longer Recommended for Use in California for COVID-19
May 28, 2021
The California Department of Public Health (CDPH) issued the following advisory.

Bamlanivimab plus Etesevimab No Longer Recommended for Use in California for COVID-19

May 28, 2021
On May 26, 2021, given the sustained increase in the P.1 and B.1.351 variants, the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) stopped the distribution of bamlanivimab plus etesevimab to California. The Centers for Disease Control and Prevention (CDC) has identified that the combined frequency of the P.1 variant and the B.1.351 variant now exceeds 10% in California. Results from in vitro assays that are used to assess the susceptibility of viral variants to particular monoclonal antibodies suggest that bamlanivimab and etesevimab administered together are not active against either the P.1 or B.1.351 variants.
The FDA recommends that health care providers in California instead use casirivimab plus imdevimab (i.e., REGEN-COV) therapy until further notice. Casirivimab plus imdevimab is an alternative monoclonal antibody therapy that is currently authorized for the same use as bamlanivimab plus etesevimab. Based on similar in vitro assay data currently available, casirivimab plus imdevimab is likely to retain activity against the P.1 and B.1.351 variants. All treatment sites can continue ordering casirivimab plus imdevimab from the authorized distributer using the direct ordering process.  
Please see the HHS/ASPR notice regarding this update for more information. 
CDPH Director's Office, MS 0500. P.O. Box 997377. Sacramento, CA 95899-7377
(916) 558-1700. (916) 568-1762 FAX
Internet address: cdph.ca.gov
To view a printable PDF of this communication and other LAHAN communications, please visit publichealth.lacounty.gov/lahan. If this message was forwarded to you, please join LAHAN here.
Manage your profile/DPH subscriptions
Opt out of all DPH subscriptions (LAHAN and Rx) using TrueRemove®
Got this as a forward? Sign up to receive our future emails.
Want to view this online? View online
powered by emma
Subscribe to our email list.